June 15, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Study demonstrates proof-of-concept for FcRn blocker nipocalimab in lupus
The neonatal Fc receptor blocker nipocalimab exhibited significant improvement over placebo in systemic lupus erythematosus at 24 and 52 weeks, according to data presented at the EULAR 2026 Congress.“Especially in lupus, IgG antibodies can be pathogenic,” said Richard A. Furie, MD, of the division of rheumatology at Northwell Health.
TL;DRAI
Nipocalimab (J&J) achieved 53.6% vs 39.7% placebo response at 52 weeks in SLE Phase 2; 75.8% in high-autoantibody patients. Anti-FcRn mechanism targeting IgG clearance advances autoimmune treatment; Phase 3 Gardenia trial signals market confidence in approach.
772 words~4 min read
